Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mobile Infrastructure CorpNONE · Entity 90772 | Director | January 17, 2017 | January 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mobile Infrastructure Corp
Report date January 17, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Convertible Redeemable Preferred StockSEC Table I · non-derivative | Direct | 26.5 |
Reported balance
Holding disclosure · report date 2017-01-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 26.5 |
| WarrantSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-01-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Warrants may be exercised after the 90th day following the occurrence of a Listing Event, at an exercise price, per share, equal to 110% of the volume weighted average closing price during the 20 trading days ending on the 90th day after the occurrence of such Listing Event; however, in no event shall the exercise price of the Warrants be less than $25 per share. F2: The Warrants will expire five years from the 90th day after the occurrence of a Listing Event. In addition, if a Listing Event does not occur on or prior to the fifth anniversary of the final Closing date of this Offering, then all outstanding Warrants will expire automatically on such anniversary date without being exercisable by the holders thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The Warrants may be exercised after the 90th day following the occurrence of a Listing Event, at an exercise price, per share, equal to 110% of the volume weighted average closing price during the 20 trading days ending on the 90th day after the occurrence of such Listing Event; however, in no event shall the exercise price of the Warrants be less than $25 per share.
F2: The Warrants will expire five years from the 90th day after the occurrence of a Listing Event. In addition, if a Listing Event does not occur on or prior to the fifth anniversary of the final Closing date of this Offering, then all outstanding Warrants will expire automatically on such anniversary date without being exercisable by the holders thereof.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ernexa Therapeutics Inc.
Report date March 24, 2021 · Filed March 27, 2021
Section 16 reporting ended · disclosed 2021-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,520 |
Reported balance
After 2021-03-24 transaction · row 1
1 source rowRow 1 · 2021-03-24 · Tax withholding · Disposed 9,944 · Balance 128,520 F1: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,100 |
Reported balance
Holding disclosure · report date 2021-03-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,100 F2: As custodian of Child 1. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,100 |
Reported balance
Holding disclosure · report date 2021-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,100 F3: As custodian of Child 2. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger.
F2: As custodian of Child 1.
F3: As custodian of Child 2.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2021 Filed Mar 27, 2021 01:54 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Tax withholdingCommon Stock | 9,944 | $2.67 | $26,550.48 |
DisclosureSEC source: 0001140361-21-010365 · form4.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · Former Director and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,520 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 207 | $3.53 | $730.71 |
DisclosureSEC source: 0001493152-21-006564 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,464 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 19, 2021. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 19, 2021. No shares were sold in connection with this transaction. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 22:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 207 | $4.81 | $995.67 |
DisclosureSEC source: 0001493152-21-004521 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,671 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 19, 2021. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 19, 2021. No shares were sold in connection with this transaction. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 22:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 2,987 | $2.55 | $7,616.85 |
DisclosureSEC source: 0001493152-21-001452 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,878 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 19, 2021. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 19, 2021. No shares were sold in connection with this transaction. Read SEC document |
| December 19, 2020 Filed Dec 22, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 170 | $2.17 | $368.90 |
DisclosureSEC source: 0001493152-20-024073 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,865 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2020. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 170 | $1.88 | $319.60 |
DisclosureSEC source: 0001493152-20-022151 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,035 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2020. No shares were sold in connection with this transaction. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 00:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 2,453 | $2.05 | $5,028.65 |
DisclosureSEC source: 0001493152-20-019769 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,205 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 21, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 21, 2020. No shares were sold in connection with this transaction. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 170 | $1.99 | $338.30 |
DisclosureSEC source: 0001493152-20-018247 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,658 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 22, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 23:05 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 170 | $2.62 | $445.40 |
DisclosureSEC source: 0001493152-20-016790 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,828 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on August 25, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on August 25, 2020. No shares were sold in connection with this transaction. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 2,453 | $1.85 | $4,538.05 |
DisclosureSEC source: 0001493152-20-014117 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,998 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on July 28, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on July 28, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 20:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 170 | $3.15 | $535.50 |
DisclosureSEC source: 0001493152-20-012285 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,451 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on June 29, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on June 29, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 20, 2020 Filed May 20, 2020 23:10 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 164 | $1.55 | $254.20 |
DisclosureSEC source: 0001493152-20-009577 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,621 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on May 20, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on May 20, 2020. No shares were sold in connection with this transaction. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 12:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 2,363 | $1.21 | $2,859.23 |
DisclosureSEC source: 0001493152-20-006883 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,785 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on April 21, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on April 21, 2020. No shares were sold in connection with this transaction. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 01:26 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 10,580 | $1.48 | $15,658.40 |
DisclosureSEC source: 0001493152-20-005355 · ownership.xml · nonDerivative · entry 2 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,222 F2 · shares: Shares issued in lieu of a cash payout of the incentive compensation earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the cash payout earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. F2 · price: Shares issued in lieu of a cash payout of the incentive compensation earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the cash payout earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 01:26 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 1,074 | $1.48 | $1,589.52 |
DisclosureSEC source: 0001493152-20-005355 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,642 F1 · shares: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the salary earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. F1 · price: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the salary earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 23:32 UTC Amendment | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 9,506 | $1.48 | $14,068.88 |
DisclosureSEC source: 0001493152-20-005524 · ownership.xml · nonDerivative · entry 2 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,148 F2 · shares: Shares issued in lieu of a cash payout of the incentive compensation earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the cash payout earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. F2 · price: Shares issued in lieu of a cash payout of the incentive compensation earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the cash payout earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 23:32 UTC Amendment | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 1,271 | $1.48 | $1,881.08 |
DisclosureSEC source: 0001493152-20-005524 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,642 F1 · shares: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the salary earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. F1 · price: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. The number of shares issued is equal to the equivalent value of the salary earned net of amounts withheld by the issuer to satisfy tax withholding requirements divided by the closing price. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 01:12 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 207 | $1.48 | $306.36 |
DisclosureSEC source: 0001493152-20-004753 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,371 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 25, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 25, 2020. No shares were sold in connection with this transaction. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 21:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 947 | $1.75 | $1,657.25 |
DisclosureSEC source: 0001493152-20-004098 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,578 F1 · shares: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. F1 · price: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 778 | $2.13 | $1,657.14 |
DisclosureSEC source: 0001493152-20-003225 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,631 F1 · shares: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. F1 · price: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 13:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 285 | $2.05 | $584.25 |
DisclosureSEC source: 0001493152-20-002966 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,853 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 25, 2020. No shares were sold in connection with this transaction. F1 · price: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 25, 2020. No shares were sold in connection with this transaction. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 877 | $1.89 | $1,657.53 |
DisclosureSEC source: 0001493152-20-002665 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,138 F1 · shares: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. F1 · price: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 743 | $2.23 | $1,656.89 |
DisclosureSEC source: 0001493152-20-001536 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,261 F1 · shares: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. F1 · price: Shares issued in lieu of salary earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The price is the closing price of the issuer's common stock on the date of issuance. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 5,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-001471 · ownership.xml · nonDerivative · entry 3 Wolff Allen · CIK 0001628529 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,518 F3 · shares: Shares issued in lieu of a cash payout of the incentive compensation earned by the reporting person. Such shares were issued under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 285 | $2.43 | $692.55 |
DisclosureSEC source: 0001493152-20-001471 · ownership.xml · nonDerivative · entry 2 Wolff Allen · CIK 0001628529 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,416 F2 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 29, 2020. No shares were sold in connection with this transaction. Read SEC document |
| January 19, 2020 Filed Feb 1, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-001471 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,701 F1 · shares: Represents shares subject to a restricted stock unit award granted under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The award will vest as to 12.5% of the shares subject to the award on the three-month anniversary of the grant date and on each three month anniversary thereafter in substantially equal installments, in each case, subject to the reporting person's continued service to the issuer as of the applicable vesting date. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 242 | $2.73 | $660.66 |
DisclosureSEC source: 0001493152-19-019540 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,701 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2019. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 241 | $2.62 | $631.42 |
DisclosureSEC source: 0001493152-19-018145 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,943 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2019. No shares were sold in connection with this transaction. Read SEC document |
| October 23, 2019 Filed Oct 23, 2019 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 241 | $2.88 | $694.08 |
DisclosureSEC source: 0001493152-19-015893 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,184 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 23, 2019. No shares were sold in connection with this transaction. Read SEC document |
| September 24, 2019 Filed Sep 24, 2019 23:43 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 722 | $2.28 | $1,646.16 |
DisclosureSEC source: 0001493152-19-014525 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,425 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 24, 2019. No shares were sold in connection with this transaction. Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:35 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 141 | $2.77 | $390.57 |
DisclosureSEC source: 0001493152-19-013436 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,147 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on August 27, 2019. No shares were sold in connection with this transaction. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 00:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 141 | $3.18 | $448.38 |
DisclosureSEC source: 0001493152-19-011371 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,288 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on July 30, 2019. No shares were sold in connection with this transaction. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 21:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 141 | $3.47 | $489.27 |
DisclosureSEC source: 0001493152-19-009632 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,429 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on June 21, 2019. No shares were sold in connection with this transaction. Read SEC document |
| May 21, 2019 Filed May 21, 2019 23:37 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 171 | $2.89 | $494.19 |
DisclosureSEC source: 0001493152-19-008043 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,570 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on May 21, 2019. No shares were sold in connection with this transaction. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 20:45 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 171 | $3.80 | $649.80 |
DisclosureSEC source: 0001493152-19-005944 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,741 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on April 23, 2019. No shares were sold in connection with this transaction. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 23:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 171 | $3.72 | $636.12 |
DisclosureSEC source: 0001493152-19-004044 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,912 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 26, 2019. No shares were sold in connection with this transaction. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:45 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-003715 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,083 F1 · shares: Represents shares subject to a restricted stock unit award granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The award will vest as to 16.67% of the shares subject to the award on the 6-month anniversary of the grant date and the remaining 83.33% of the shares will vest in 30 substantially equal monthly installments beginning on the 7-month anniversary of the grant date, in each case, subject to the reporting person's continued service to the issuer as of the applicable vesting date. Read SEC document |
| February 26, 2019 Filed Feb 26, 2019 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 171 | $3.42 | $584.82 |
DisclosureSEC source: 0001493152-19-002609 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,083 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 26, 2019. No shares were sold in connection with this transaction. Read SEC document |
| January 29, 2019 Filed Jan 30, 2019 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 171 | $3.18 | $543.78 |
DisclosureSEC source: 0001493152-19-001144 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,254 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 29, 2019. No shares were sold in connection with this transaction. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 145 | $2.00 | $290.00 |
DisclosureSEC source: 0001493152-18-017753 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,425 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2018. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 144 | $2.87 | $413.28 |
DisclosureSEC source: 0001493152-18-016584 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,570 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2018. No shares were sold in connection with this transaction. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 12:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 145 | $4.32 | $626.40 |
DisclosureSEC source: 0001493152-18-014819 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,714 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 23, 2018. No shares were sold in connection with this transaction. Read SEC document |
| September 25, 2018 Filed Sep 25, 2018 20:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 857 | $4.23 | $3,625.11 |
DisclosureSEC source: 0001493152-18-013716 · ownership.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,859 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 25, 2018. No shares were sold in connection with this transaction. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:01 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-003720 · form4.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,716 F1 · shares: Represents shares subject to a restricted stock unit award granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The award will vest as to 16.67% of the shares subject to the award on the 6-month anniversary of the grant date and the remaining 83.33% of the shares will vest in 30 substantially equal monthly installments beginning on the 7-month anniversary of the grant date, in each case, subject to the reporting person's continued service to the issuer as of the applicable vesting date. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 01:47 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 7,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-002428 · form4.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,716 F1 · shares: Shares issued in lieu of a cash payout of the incentive compensation earned by the reporting person under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan and pursuant to the NTN Buzztime, Inc. Executive Incentive Plan for Eligible Employees of NTN Buzztime, Inc. Fiscal Year 2016, as amended (the 2016 EIP). Under the 2016 EIP, the decision to pay the incentive compensation earned in shares instead of in cash is made by the Nominating and Corporate Governance/Compensation Committee of the Board of Directors of the issuer at its discretion and in its sole determination. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 01:48 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 250 | $7.47 | $1,867.50 |
DisclosureSEC source: 0001493152-16-015200 · form4.xml · nonDerivative · entry 3 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,100 F2 · ownership.nature: As custodian of Minor Child 2. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 01:48 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 250 | $7.47 | $1,867.50 |
DisclosureSEC source: 0001493152-16-015200 · form4.xml · nonDerivative · entry 2 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,100 F1 · ownership.nature: As custodian of Minor Child 1. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 01:48 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 500 | $7.46 | $3,730.00 |
DisclosureSEC source: 0001493152-16-015200 · form4.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,210 Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 00:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 1,750 | $6.64 | $11,620.00 |
DisclosureSEC source: 0001493152-16-014599 · form4.xml · nonDerivative · entry 3 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,410 F2 · ownership.nature: As custodian of Minor Child 2. Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 00:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 1,750 | $6.64 | $11,620.00 |
DisclosureSEC source: 0001493152-16-014599 · form4.xml · nonDerivative · entry 2 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 29,660 F1 · ownership.nature: As custodian of Minor Child 1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.